Rezolute, Inc. (RZLT) - Q1 2026 (Ended Sept 30, 2025) Filing Summary
Business Context and Reporting Period
Rezolute, Inc. is a late-stage rare disease company focused on developing biologics for hypoglycemia caused by hyperinsulinism. The primary clinical asset is ersodetug, currently in Phase 3 trials for congenital hyperinsulinism (sunRIZE study) and tumor hyperinsulinism (upLIFT study). The company has no commercial revenue and operates as a single reportable segment. This report covers the three months ended September 30, 2025.
Key Financial Metrics
| Metric | Q1 2026 (Sept 30, 2025) | Q1 2025 (Sept 30, 2024) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(18.2) million | $(15.4) million |
| Operating Expenses | $19.8 million | $16.9 million |
| Research & Development (R&D) | $13.1 million | $12.8 million |
| General & Administrative (G&A) | $6.7 million | $4.2 million |
| Net Cash Used in Operating Activities | $(17.4) million | $(16.0) million |
| Cash & Cash Equivalents | $9.1 million | $10.5 million |
| Marketable Debt Securities | $143.1 million | $73.8 million |
| Total Capital Resources | $152.2 million | $84.3 million |
| Accumulated Deficit | $(422.0) million | $(344.8) million |
Material Changes vs. Prior Period
- Expense Growth: Total operating expenses increased by $2.9 million (17%) year-over-year. G&A expenses rose significantly by $2.5 million (59%), driven by increased compensation and business development activities in preparation for commercialization. R&D expenses increased by $0.4 million (3%), with higher compensation and patient affairs costs offset by lower manufacturing spend.
- Liquidity Position: Total capital resources increased to $152.2 million from $84.3 million in the prior year, primarily due to a $96.8 million net proceeds from an underwritten offering in April 2025 and a $4.2 million private placement in June 2025. The company deployed $88.9 million into marketable debt securities during the quarter.
- Share Count: Weighted average shares outstanding increased to 103.4 million from 69.7 million, reflecting equity issuances and the exercise of pre-funded warrants.
Outlook, Risks, and Management Commentary
- Clinical Milestones: Topline data for the sunRIZE Phase 3 study (congenital HI) is anticipated in December 2025. The upLIFT Phase 3 study (tumor HI) is ongoing, with topline data expected in the second half of 2026. A Biologics License Application (BLA) is targeted for mid-2026 pending supportive data.
- Liquidity Runway: Management believes current capital resources ($152.2 million) are sufficient to fund operations and clinical trials for at least 12 months from the filing date.
- Contractual Obligations: A $25.0 million milestone payment is due to XOMA upon regulatory approval of ersodetug. Additional potential milestones up to $185.0 million (XOMA) and $46.5 million (ActiveSite) are contingent on future sales and regulatory events.
- Risks: The company remains pre-revenue and expects to incur losses for the foreseeable future. Success depends on clinical trial outcomes, regulatory approvals, and the ability to secure additional financing for long-term needs.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $17.4 million quarterly operating cash burn against the $152.2 million capital base.
- Clinical Timelines: Monitor the December 2025 sunRIZE topline data release and the progress of the upLIFT study enrollment.
- Milestone Liabilities: Assess the probability and timing of the $25.0 million regulatory milestone payment to XOMA.
- Dilution Risk: Review the impact of outstanding pre-funded warrants (12.6 million shares) and stock options (13.4 million shares) on future share count.
- Investment Portfolio: Confirm the credit quality and maturity profile of the $143.1 million in marketable debt securities.